

Antidepressant use in gastroenterology

Citation for published version (APA):

Keszthelyi, D. (2020). Antidepressant use in gastroenterology: overcoming hurdles. *Neurogastroenterology and Motility*, 32(10), Article e13982. <https://doi.org/10.1111/nmo.13982>

Document status and date:

Published: 01/10/2020

DOI:

[10.1111/nmo.13982](https://doi.org/10.1111/nmo.13982)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Antidepressant use in gastroenterology: Overcoming hurdles

I read with interest the article by Yan et al.¹ addressing an important topic in clinical gastroenterology practice: the stigma associated with the prescription of antidepressants. In their conclusions, the authors recommend "physicians should help patients establish the right knowledge to defeat stigma [...] toward antidepressant agents."

In fact, this all comes down to the way doctors communicate with patients about the use of antidepressants. This, however, is easier said than done. It requires the sufficient amount of time (which we may not readily have at our disposal) and the appropriate communication skills. In addition, there are considerable hurdles on the side of the physicians (in particular non-psychiatrists), who might not feel comfortable or competent in prescribing psychoactive drugs for gastrointestinal symptoms.

Interestingly, Yan et al. also state that "prescribing antidepressants to patients without psychological symptoms might lead to ethical issues in our hospital." This further highlights another obstacle, that is, the fact that antidepressants are prescribed off-label. In fact, at least in UK primary practice, two-thirds of all antidepressants are prescribed off-label. For TCAs, the prevalence of off-label indications is 81% (93% for amitriptyline).² It is a peculiar situation when a drug is almost universally used off-label rather than on-label. Guidelines indeed advocate for the use of TCAs in both IBS³ and FD,⁴ and the medical-scientific community should engage with regulatory authorities to resolve this unorthodoxy by drug repurposing. It is unrealistic to expect randomized clinical trials being conducted for off-label drug indications, especially for an old (and inexpensive) drug such as amitriptyline that is no longer owned by an innovator company.

In addition, when initiating discussion on starting an antidepressant in gastroenterology clinics, one should be aware of the following:

1. Gastroenterologists should consider functional disorders as being disorders of the gut-brain interaction. The term "functional" has a negative connotation, and many colleagues still use this as a synonym for psychiatric comorbidity.
2. Antidepressants in the context of treating gastrointestinal disorders should be referred to as neuromodulators.⁵
3. Inappropriate communication on side effects can introduce nocebo effects and decreased adherence to therapy. Symptoms presumed to be side effects may in fact have already been present prior to starting treatment and can be interpreted as verbalization of the patient's anxiety about side effects.⁶

Adhering to such communication strategies has the potential to increase therapeutic efficacy, thereby contributing to satisfaction with treatment at both ends: patients and physicians.

DISCLOSURES

The author has received research funding from Will Pharma, Grunenthal, and Allergan and has served on the advisory board for Bayer and Biocodex.

Daniel Keszthelyi 

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Correspondence

Daniel Keszthelyi, Department of Internal Medicine, Division of Gastroenterology-Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.
Email: daniel.keszthelyi@maastrichtuniversity.nl

ORCID

Daniel Keszthelyi  <https://orcid.org/0000-0001-9856-9980>

REFERENCES

1. Yan XJ, Luo QQ, Qiu HY, Ji CF, Chen SL. The impact of stigma on medication adherence in patients with functional dyspepsia. *Neurogastroenterol Motil.* 2020;e13956.
2. Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ.* 2017;356:j603.
3. Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. *Am J Gastroenterol.* 2018;113:1-18.
4. Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. *Am J Gastroenterol.* 2017;112:988-1013.
5. Drossman DA, Tack J, Ford AC, Szegedy E, Tornblom H, Van Oudenhove L. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome foundation working team report. *Gastroenterology.* 2018;154(4):1140.e1-1171.e1.
6. Thiwan S, Drossman DA, Morris CB, et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. *Clin Gastroenterol Hepatol.* 2009;7:446-451.